POLRMT

Across TCGA pan-cancer cohorts, POLRMT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POLRMT data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POLRMT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated POLRMT expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where POLRMT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.891	0.489	<.001	31	view →
PDAC	OS	Quartile	All	0.395	0.576	.023	15	view →
UCEC	DFS	Median	All	0.832	0.976	.003	12	view →
CCRCC	DFS	Tertile	II,III,IV	0.531	0.722	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

POLRMT–LSCC (DFS)

Open the LSCC breakdown →